Immuneering Corporation (IMRX) DCF Valuation

Inmuneing Corporation (IMRX) DCF Valoración

US | Healthcare | Biotechnology | NASDAQ
Immuneering Corporation (IMRX) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Immuneering Corporation (IMRX) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Optimice su tiempo y aumente la precisión con nuestra calculadora DCF (IMRX)! Utilizando los datos de la corporación de inmunerización real y los supuestos ajustables, esta herramienta le permite pronosticar, analizar y valor (IMRX) como un inversor experimentado.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 1.9 2.3 2.1 .3 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 20.41 -10.02 -84.76 -100 -43.59 -43.59 -43.59 -43.59 -43.59
EBITDA -7.3 -17.0 -33.7 -51.5 -58.1 .0 .0 .0 .0 .0
EBITDA, % -382.35 -735.58 -1619.46 -16238.3 100 -60 -60 -60 -60 -60
Depreciation .0 .1 .2 .8 .4 .0 .0 .0 .0 .0
Depreciation, % 0.94176 3.43 7.65 251.39 100 42.4 42.4 42.4 42.4 42.4
EBIT -7.4 -17.1 -33.8 -52.3 -58.4 .0 .0 .0 .0 .0
EBIT, % -383.29 -739.01 -1627.11 -16489.69 100 -60 -60 -60 -60 -60
Total Cash 13.8 37.1 149.2 105.5 85.7 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .2 .5 .2 .0 .0
Account Receivables, % 10.94 21.64 11.83 3.92 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 0 0.000315505187 100 20 20 20 20 20
Accounts Payable .3 1.5 1.4 3.2 2.1 .0 .0 .0 .0 .0
Accounts Payable, % 15.36 64.05 67.04 995.28 100 69.29 69.29 69.29 69.29 69.29
Capital Expenditure .0 -.1 -.1 -.7 -.3 .0 .0 .0 .0 .0
Capital Expenditure, % -1.07 -2.31 -2.92 -234.26 100 -21.26 -21.26 -21.26 -21.26 -21.26
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -7.7 -17.1 -33.5 -51.0 -58.4 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -7.6 -16.2 -33.3 -48.9 -59.4 -2.1 .0 .0 .0 .0
WACC, % 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33
PV UFCF
SUM PV UFCF -2.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -55
Equity Value 53
Diluted Shares Outstanding, MM 28
Equity Value Per Share 1.86

What You Will Get

  • Comprehensive Financial Model: Leverage Immuneering’s actual data for accurate DCF valuation.
  • Complete Forecast Flexibility: Modify revenue growth, margins, WACC, and other essential drivers.
  • Real-Time Calculations: Automatic updates provide immediate results as adjustments are made.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
  • Adaptable and Reusable: Designed for versatility, allowing for ongoing use in detailed forecasts.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Immuneering Corporation (IMRX).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to IMRX.
  • Customizable Forecast Assumptions: Update growth projections, capital expenditures, and discount rates as needed.
  • Incorporated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Immuneering Corporation (IMRX).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Immuneering Corporation (IMRX) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Immuneering Corporation’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Immuneering Corporation (IMRX)?

  • All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for IMRX.
  • Flexible Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
  • In-Depth Analysis: Automatically computes Immuneering's intrinsic value and Net Present Value.
  • Rich Data Repository: Access historical and projected data for reliable analysis.
  • Expert-Level Tool: Perfect for financial analysts, investors, and business advisors focused on IMRX.

Who Should Use This Product?

  • Individual Investors: Gain insights to make informed decisions about investing in Immuneering Corporation (IMRX).
  • Financial Analysts: Enhance your valuation processes with comprehensive financial models tailored for Immuneering Corporation (IMRX).
  • Consultants: Provide clients with expert valuation analysis of Immuneering Corporation (IMRX) efficiently and effectively.
  • Business Owners: Learn from the valuation strategies of biotech companies like Immuneering Corporation (IMRX) to refine your own business approach.
  • Finance Students: Explore valuation methodologies using real data and case studies from Immuneering Corporation (IMRX).

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Immuneering Corporation (IMRX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Immuneering Corporation (IMRX).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.